TRX-2基因表达在急性白血病微小残留病灶监测中的作用  

Expression of thioredoxin-2 for monitoring minimal residual disease in acute leukemia

作　　者：罗琼[1] 黄志新[1] 罗柳萍[1] 肖定璋[2] 

机构地区：[1]广东省人民医院,广东省医学科学院血液科,广州510080 [2]广东省人民医院,广东省医学科学院医学研究中心,广州510080

出　　处：《中南大学学报（医学版）》2013年第4期383-387,共5页Journal of Central South University ：Medical Science

基　　金：广州市科技计划项目(2011J4100009)~~

摘　　要：目的:探讨硫氧还蛋白-2(TRX-2)基因表达在急性白血病(AL)微小残留病灶(MRD)监测中的价值。方法:采用实时荧光定量聚合酶反应(RQ-PCR)检测AL初发组(68例)、血液学完全缓解(CHR)组(57例)和复发组(25例)TRX-2基因表达的变化,25名骨髓捐献者作为正常对照组,TRX-2基因表达量的上限(91)为参考值上限,回顾分析复发组在CHR期(骨髓原始细胞计数<5%)TRX-2基因表达的水平,比较其与流式细胞术(FCM)检测的MRD的相关性。结果:TRX-2基因表达在完全缓解组与初治组和复发组之间差异有统计学意义(P<0.01);复发患者CHR期(骨髓原始细胞<5%),21例(21/25)TRX-2基因呈高表达(>91),与流式细胞术检测的MRD具有相关性(r=0.874,P=0.0005)。结论:TRX-2基因为急性白血病新的广谱标志,适用于MRD的监测。Objective： To investigate the significance of human thioredoxin-2 （TRX-2） in monitoring minimal residual disease （MRD） in acute leukemia （AL）. Methods： We used real-time quantitative PCR to serially quantitize TRX-2 expression levels in the bone marrow of AL patients at diagnosis （n=68）, at complete hematologic remission （CHR, n=S7） and at relapse （n=25）. Another 25 normal donors served as normal controls. The upper limit ofthe bone marrow at 91 was regarded as the reference. TRX-2 expression level at CHR with 〈5% blast cells in the bone marrow of relapse patients was analyzed and compared with MRD by flow cytometry. Results： The TRX-2 levels between the CHR patients and newly diagnosed patients, and between the CHR patients and the relapse patients had significant difference. TRX-2 expression level of 21（21/25） relapse patients at CHR with 〈5% blast cells in the bone marrow was higher than the reference （〉91）. TRX-2 level was correlated to the expression level of MRD. Conclusion： TRX-2 may be the marker for AL and used in MRD monitoring.

关 键 词：TRX-2基因 急性白血病 微小残留病灶 实时荧光定量聚合酶反应 

分 类 号：R733.7[医药卫生—肿瘤]